A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia

Leukemia Research

Volumn 23, Issue 9, 1999, Pages 787-794

  Karanes, Chatchada ^a   Kopecky, Kenneth J ^b,j   Head, David R ^k   Grever, Michael R ^c   Hynes, Harry E ^d   Kraut, Eric H ^e   Vial, Richard H ^f   Lichtin, Alan ^g   Nand, Sucha ^h   Samlowski, Wolfram E ⁱ   Appelbaum, Frederick R ^j  

^a WAYNE STATE UNIVERSITY   (United States)

^b SW Oncol Group Statistical Center   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f LOUISIANA STATE UNIVERSITY   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h LOYOLA UNIVERSITY CHICAGO   (United States)

ⁱ UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^j Fred Hutchinson Cancer Research Center   (United States)

^k ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

more..

Author keywords

Acute myeloid leukemia; High dose ARA C; Mitoxantrone

Indexed keywords

CYTARABINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MITOXANTRONE; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 0032809362     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00087-9     Document Type: Article

References (15)

1. Herzig R.H., Wolff S.N., Lazarus H.M., Fay J.W., Lin H.S., Shina D.C. et al. High-dose cytosine arabinoside therapy for refractory leukemia. Blood. 62:1983;361.
2. Herzig R.H., Lazarus H.M., Wolff S.N., Phillips G.L., Herzig G.P. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J. Clin. Oncol. 3:1985;992-997.
3. Philips G.L., Reece D.E., Shepherd J.D., Barnett M.J., Brown R.A., Frei-Lahr D.A. et al. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood. 77:1991;1429-1435.
4. Hines J.D., Mazza J.J., Oken M.M., Adelstein D.J., Keller A., Bennett J.M. et al. Prolonged survival after high-dose cytosine arabinoside and amsacrine induction in patients with previously untreated de novo acute nonlymphocytic leukemia. Semin. Oncol. 14:1987;37-39.
5. Weick J.K., Kopecky K.J., Appelbaum F.R., Head D.R., Kingsbury L.L., Balcerzak S.P. et al. A randomized investigation of high dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology group study. Blood. 88:1996;2841-2851.
6. Wolff S.N., Marion J., Stein R.S., Flexner J.M., Lazarus H.M., Spitzer T.R. et al. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study. Blood. 65:1985;1407-1411.
7. Heil G., Mitrou P.S., Hoetzer D., Freund M., Link H., Ehninger G. et al. High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long term follow-up of a prospective randomized multicenter trial. Ann. Hematol. 71:1995;219-225.
8. Karanes C., Kopecky K.J., Durie B.G.M., Grever M.R. Increased risk of early death (ED) with high dose ARA-C (HDAC) and m-AMSA compared to HDAC alone or HDAC and mitoxantrone (MITOX) in high risk nonlymphocytic leukemia (ANL). Proceedings of American Society of Clinical Oncology. 8:1989;201a.
9. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
10. Mantel N. Evaluation of survival data and two new rank order statistics arising from its consideration. Cancer Chemother. Rep. 50:1966;163-170.
11. Cox D.R. Analysis of Binary Data. 1970;Chapman and Hall, London.
12. Cox D.R. Regression analysis and life tables. J. R. Stat. Soc. B. 34:1972;187-220.
13. Larson R.A., Day R.S., Azarnia N., Bennett J.M., Browman G., Goldberg J. et al. The selective use of AMSA following high dose cytarabine in patients with acute myeloid leukemia in relapse: a Leukemia Intergroup Study. Br. J. Hematol. 82:1992;337-346.
14. Gale R.P., Horowitz M.M., Rees J.K., Gray R.G., Oken M.M., Estey E.H. et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia. 10:1996;13-19.
15. Thalhammer F., Geissler K., Jager U., Kyrle P.A., Pabinger I., Mitterbauer M. et al. Duration of second remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-canter study. Annals. of. Hematology. 72:1996;216-222.